TY - JOUR
T1 - Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis
AU - Schwarz, Carsten
AU - Vandeputte, Patrick
AU - Rougeron, Amandine
AU - Giraud, Sandrine
AU - de Bernonville, Thomas Dugé
AU - Duvaux, Ludovic
AU - Gastebois, Amandine
AU - Alastruey-Izquierdo, Ana
AU - Martín-Gomez, Maria Teresa
AU - Martin Mazuelos, Estrella
AU - Sole, Amparo
AU - Cano, Josep
AU - Pemán, Javier
AU - Quindos, Guillermo
AU - Botterel, Françoise
AU - Bougnoux, Marie-Elisabeth
AU - Chen, Sharon
AU - Delhaès, Laurence
AU - Favennec, Loïc
AU - Ranque, Stéphane
AU - Sedlacek, Ludwig
AU - Steinmann, Joerg
AU - Vazquez, Jose
AU - Williams, Craig
AU - Meyer, Wieland
AU - Le Gal, Solene
AU - Nevez, Gilles
AU - Fleury, Maxime
AU - Papon, Nicolas
AU - Symoens, Francoise
AU - Bouchara, Jean-Philippe
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Cystic fibrosis (CF) is the major genetic inherited disease in Caucasian populations. The respiratory tract of CF patients displays a sticky viscous mucus, which allows for the entrapment of airborne bacteria and fungal spores and provides a suitable environment for growth of microorganisms, including numerous yeast and filamentous fungal species. As a consequence, respiratory infections are the major cause of morbidity and mortality in this clinical context. Although bacteria remain the most common agents of these infections, fungal respiratory infections have emerged as an important cause of disease. Therefore, the International Society for Human and Animal Mycology (ISHAM) has launched a working group on Fungal respiratory infections in Cystic Fibrosis (Fri-CF) in October 2006, which was subsequently approved by the European Confederation of Medical Mycology (ECMM). Meetings of this working group, comprising both clinicians and mycologists involved in the follow-up of CF patients, as well as basic scientists interested in the fungal species involved, provided the opportunity to initiate collaborative works aimed to improve our knowledge on these infections to assist clinicians in patient management. The current review highlights the outcomes of some of these collaborative works in clinical surveillance, pathogenesis and treatment, giving special emphasis to standardization of culture procedures, improvement of species identification methods including the development of nonculture-based diagnostic methods, microbiome studies and identification of new biological markers, and the description of genotyping studies aiming to differentiate transient carriage and chronic colonization of the airways. The review also reports on the breakthrough in sequencing the genomes of the main Scedosporium species as basis for a better understanding of the pathogenic mechanisms of these fungi, and discusses treatment options of infections caused by multidrug resistant microorganisms, such as Scedosporium and Lomentospora species and members of the Rasamsonia argillacea species complex.
AB - Cystic fibrosis (CF) is the major genetic inherited disease in Caucasian populations. The respiratory tract of CF patients displays a sticky viscous mucus, which allows for the entrapment of airborne bacteria and fungal spores and provides a suitable environment for growth of microorganisms, including numerous yeast and filamentous fungal species. As a consequence, respiratory infections are the major cause of morbidity and mortality in this clinical context. Although bacteria remain the most common agents of these infections, fungal respiratory infections have emerged as an important cause of disease. Therefore, the International Society for Human and Animal Mycology (ISHAM) has launched a working group on Fungal respiratory infections in Cystic Fibrosis (Fri-CF) in October 2006, which was subsequently approved by the European Confederation of Medical Mycology (ECMM). Meetings of this working group, comprising both clinicians and mycologists involved in the follow-up of CF patients, as well as basic scientists interested in the fungal species involved, provided the opportunity to initiate collaborative works aimed to improve our knowledge on these infections to assist clinicians in patient management. The current review highlights the outcomes of some of these collaborative works in clinical surveillance, pathogenesis and treatment, giving special emphasis to standardization of culture procedures, improvement of species identification methods including the development of nonculture-based diagnostic methods, microbiome studies and identification of new biological markers, and the description of genotyping studies aiming to differentiate transient carriage and chronic colonization of the airways. The review also reports on the breakthrough in sequencing the genomes of the main Scedosporium species as basis for a better understanding of the pathogenic mechanisms of these fungi, and discusses treatment options of infections caused by multidrug resistant microorganisms, such as Scedosporium and Lomentospora species and members of the Rasamsonia argillacea species complex.
KW - cystic fibrosis
KW - fungal respiratory infections
KW - biological diagnosis
KW - pathogenic mechanisms
KW - treatment
KW - Scedosporium species
U2 - 10.1093/mmy/myx106
DO - 10.1093/mmy/myx106
M3 - Article
SN - 1369-3786
VL - 56
SP - S42-S59
JO - Medical Mycology
JF - Medical Mycology
IS - Supplement 1
ER -